Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 10/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 9/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933356 | 0.97 | PARP10 (0.52) | PARP10PARP15PARP2SIRT2MAOB | |
| SCHEMBL24932946 | 0.90 | XDH (0.42) | PARP10PARP15PARP2CHEK2FFAR4 | |
| SCHEMBL24933470 | 0.89 | XDH (0.44) | PARP10PARP15PARP2CHEK2 | |
| SCHEMBL24933789 | 0.89 | CHEK2 (0.42) | PARP10PARP15PARP2MAOAMAOB | |
| SCHEMBL24933656 | 0.88 | CHEK2 (0.43) | PARP10PARP15PARP2MAOAMAOB | |
| SCHEMBL29203336 | 0.87 | CHEK2 (0.52) | PARP10PARP15PARP2CHEK2 | |
| SCHEMBL24933593 | 0.87 | RAB9A (0.44) | PARP10HPGD | |
| SCHEMBL24933589 | 0.87 | XDH (0.49) | PARP10PARP15PARP2CHEK2 | |
| SCHEMBL24933017 | 0.86 | PRKAB2 (0.42) | PARP10PARP15PARP2CHEK2FFAR4 | |
| SCHEMBL24933494 | 0.85 | IRAK4 (0.41) | PARP10PARP15PARP2CHEK2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |